Lipe & Dalton’s Exelixis EXEL Stock Holding History

Lipe & Dalton’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,625	Closed	-$133K	–	101
2020 Q4	$133K	Buy	+6,625	New	+$139K	0.08%	75

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Lipe & Dalton's EXEL Position: Q1 2021 in Review

Lipe & Dalton sold out of Exelixis (EXEL) in Q1 2021, closing a stake of 6,625 shares — an estimated $133K sold.

Lipe & Dalton first reported a position in EXEL in Q4 2020 and held it in 1 quarter. The position peaked at $133K in Q4 2020. 347 funds tracked by Wall St. Rank hold EXEL as of Q1 2021.

Lipe & Dalton reported no remaining Exelixis position as of Q1 2021 after selling out during the quarter.
Lipe & Dalton sold 6,625 Exelixis shares in Q1 2021, an estimated $133K.
Lipe & Dalton first reported a position in Exelixis in Q4 2020 and held it in 1 quarter.
Lipe & Dalton's Exelixis position peaked at $133K in Q4 2020.
347 funds tracked by Wall St. Rank held Exelixis as of Q1 2021.

Based on Lipe & Dalton's 13F filing for Q1 2021, filed 30 Apr 2021.